Traders Buy High Volume of Gossamer Bio Call Options (NASDAQ:GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSS) was the recipient of unusually large options trading on Monday. Stock investors purchased 28,224 call options on the stock. This represents an increase of 417% compared to the typical volume of 5,460 call options.

Analyst Upgrades and Downgrades

Several analysts have commented on GOSS shares. Barclays began coverage on shares of Gossamer Bio in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Gossamer Bio has an average rating of “Moderate Buy” and a consensus target price of $8.60.

Gossamer Bio Trading Up 8.8%

Shares of NASDAQ GOSS opened at $2.48 on Tuesday. The company has a market cap of $574.01 million, a P/E ratio of -3.59 and a beta of 1.92. Gossamer Bio has a 12-month low of $0.76 and a 12-month high of $3.87. The stock has a fifty day moving average price of $3.03 and a 200 day moving average price of $2.65.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. The business had revenue of $13.29 million for the quarter, compared to analyst estimates of $6.32 million. On average, sell-side analysts forecast that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Gossamer Bio

Several hedge funds and other institutional investors have recently modified their holdings of GOSS. Legal & General Group Plc bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at approximately $26,000. Ciovacco Capital Management LLC acquired a new position in Gossamer Bio in the third quarter worth $27,000. Banco BTG Pactual S.A. bought a new stake in Gossamer Bio during the second quarter valued at $27,000. Drive Wealth Management LLC raised its holdings in shares of Gossamer Bio by 52.7% during the second quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock worth $31,000 after purchasing an additional 8,797 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Gossamer Bio during the fourth quarter worth $35,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.